GO
Loading...

Medtronic PLC

More

  • *Action may deter Pfizer from returning to bid for AstraZeneca. Burger King, which is in the process of an inversion deal with Canada's Tim Horton's, said Tuesday it would proceed with its $11.5 billion deal despite the Treasury actions, saying the transaction was not about the tax benefits.

  • Tax inversion move: Bitter pill for deals to swallow Tuesday, 23 Sep 2014 | 8:46 AM ET

    The US government has been promising a crackdown on tax inversion deals for months. Yet the measures announced Monday may not be disincentive enough.

  • *May deter Pfizer from returning to bid for AstraZeneca. LONDON, Sept 23- Shares in drugmakers AstraZeneca and Shire fell sharply on Tuesday after the U.S. The move could jeopardize an agreed deal for AbbVie to buy Shire for $55 billion and deter Pfizer from making another attempt to acquire AstraZeneca, after a $118 billion takeover attempt failed in May.

  • WASHINGTON, Sept 22- Moving against tax-avoidance by corporations, the Obama administration is taking several actions to curb deals known as "inversions" that allow companies to escape U.S. taxes by reincorporating abroad.

  • Treasury takes actions to deter tax inversions Monday, 22 Sep 2014 | 6:00 PM ET
    Jack Lew

    The issue of so-called tax inversions has been a major policy point for President Barack Obama over the past few months.

  • Capital pains: Medtronic inversion ires investors Monday, 22 Sep 2014 | 1:30 PM ET
    Medtronic Chairman and Chief Executive Omar Ishrak.

    Medtronic's plan to reimburse execs and directors for $63 million in excise taxes from a tax inversion draws heat from shareholders.

  • NEW YORK, Sept 16- Some of the top 20 investors at Salix Pharmaceuticals Ltd are threatening to vote down a proposed deal to buy a unit of Cosmo Pharmaceuticals SpA, and are pressing Salix to consider selling itself instead, people familiar with the matter said on Tuesday.

  • LONDON, Sept 16- Roche's decision to buy U.S. biotech company InterMune for $8.3 billion last month was "exceptional" and not a sign of more ambitious plans for major acquisitions, the Swiss drugmaker's chief executive said on Tuesday.

  • NEW YORK, Sept 11- U.S. specialty drugmaker Akorn Inc is exploring a bid for Belgian drugmaker UCB SA's U.S. subsidiary, a deal that would allow the company to move its tax domicile overseas in a practice known as inversion, according to people familiar with the matter.

  • Inversions threaten to 'erode' tax base: CVS CEO Wednesday, 3 Sep 2014 | 11:02 AM ET

    Washington must address corporate tax inversions before the tactic further destroys the U.S. corporate tax base, says CVS CEO Larry Merlo.

  • NEW YORK, Sept 3- Some of the best-known technology investors are looking beyond their tried-and-true Internet plays to bet on healthcare data as the next growth market.

  • Public pension funds stay mum on tax inversions Tuesday, 2 Sep 2014 | 8:07 AM ET
    The offices of the California Public Employees' Retirement System (Calpers) are shown in Sacramento, Calif.

    Public pension funds have major stakes in American firms moving overseas to cut their tax bills. But they are saying little about the strategy.

  • Aug 28- Johnson& Johnson plans to seek a buyer for its medical device maker business, Cordis Corp, The Wall Street Journal reported citing people familiar with the matter. Earlier this year, J&J sold another of its units, Ortho-Clinical Diagnostics Inc to private-equity firm Carlyle Group for $4.15 billion.

  • Bankers and lawyers providing takeover advice said on Monday that Burger King Worldwide Inc's intention to move its tax domicile overseas through a so-called inversion deal- in this case the purchase of Canada's Tim Hortons- shouldn't be seen as a sign of a lot more deals to come.

  • Burger King in merger talks with Tim Hortons Sunday, 24 Aug 2014 | 9:28 PM ET

    Burger King is in talks to combine with Tim Hortons in a deal that would create a powerhouse with a market capitalization of roughly $18 billion.

  • *Deal boosts Roche presence in respiratory medicine. LONDON/ ZURICH, Aug 24- Roche Holding AG has agreed to buy U.S. biotech company InterMune Inc for $8.3 billion in cash, marking the latest multibillion-dollar deal in a consolidating pharmaceutical sector.

  • Roche to purchase InterMune in $8.3 billion deal Sunday, 24 Aug 2014 | 12:27 PM ET

    Biotech firm Roche announced plans Sunday to buy InterMune for $8.3 billion on a fully diluted basis in an all-cash transaction.

  • Aug 19- Medtronic Inc Chief Executive Omar Ishrak defended his company's plan to acquire Dublin- based Covidien Plc in a so-called inversion deal, saying the medical device maker will be able to create more U.S. jobs while still paying substantial taxes once the transaction closes.

  • Stock futures add to gains after CPI, housing starts Tuesday, 19 Aug 2014 | 8:46 AM ET

    U.S. stock-index futures pointed to a higher open on Tuesday, as global markets continued to rebound on waning Ukraine-Russia tensions.

  • Aug 19- Medtronic Inc reported the strongest quarterly U.S. sales growth for its medical devices in five years and said it was committed to completing the acquisition of Irish-domiciled Covidien Plc by the end of the year or early 2015.. Minneapolis- based Medtronic also confirmed its full-year profit and revenue outlook on Tuesday.